CDC148: A Potential Drug Target and Biomarker for Cancer (G130940)

Target Name: CCDC148

NCBI ID: G130940

CCDC148

CDC148: A Potential Drug Target and Biomarker for Cancer

CCDC148 (CC148_HUMAN), also known as human carcinoembryonic development (HCD), is a protein that plays a crucial role in the development and progression of cancer. It is a transcription factor that is expressed in a wide range of tissues and cells, including epithelial, Mesenchymal, and Neural tissues. CCDC148 has been identified as a potential drug target and a biomarker for various types of cancer, including breast, lung, and ovarian cancer.

CDC148 is a 21-kDa transmembrane protein that is expressed in various tissues, including the brain, pancreas, heart, and blood vessels. It is a key regulator of cell proliferation and has been implicated in the development and progression of cancer. CCDC148 has been shown to promote the growth and survival of cancer cells, and it has been used as a potential drug target in various clinical trials.

One of the most promising aspects of CCDC148 is its potential as a drug target is its ability to interact with several different signaling pathways. CCDC148 has been shown to interact with several different signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT signaling pathways. It has been shown to play a role in these signaling pathways by regulating the activity of several different proteins, including Smad, TGF-β1, NF-kappa-B, and PI3K.

CDC148 has also been shown to be involved in several different signaling pathways that are involved in cancer progression. For example, CCDC148 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in cancer. It has been shown to promote the formation of new blood vessels in cancer cells, which can provide them with the oxygen and nutrients they need to grow and survive.

Another promising aspect of CCDC148 is its ability to serve as a biomarker for cancer. CCDC148 has been shown to be expressed in a wide range of cancer tissues and has been used as a biomarker in several clinical trials. For example, CCDC148 has been shown to be upregulated in breast cancer and has been used as a biomarker for the diagnosis and prognosis of breast cancer.

CDC148 has also been shown to be involved in several different signaling pathways that are involved in cancer treatment. For example, CCDC148 has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together and form tissues. It has been shown to play a role in the regulation of cell adhesion, which can make it more difficult for cancer cells to stick together and form tumors.

In conclusion, CCDC148 is a protein that plays a crucial role in the development and progression of cancer. It is a transcription factor that is expressed in a wide range of tissues and cells and has been shown to promote the growth and survival of cancer cells. CCDC148 is also a potential drug target and a biomarker for various types of cancer, including breast, lung, and ovarian cancer. Further research is needed to fully understand the role of CCDC148 in cancer development and treatment.

Protein Name: Coiled-coil Domain Containing 148

The "CCDC148 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC148 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets